Recombinant VEGF (Ranibizumab Biosimilar) antibody
Reactivity: Human
FACS, in vivo
Host: Mouse
Monoclonal
unconjugated
Fab fragment
Recombinant Antibody
-
- Target See all VEGF (Ranibizumab Biosimilar) products
- VEGF (Ranibizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Fragment
- Fab fragment
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This VEGF (Ranibizumab Biosimilar) antibody is un-conjugated
- Application
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- Purpose
- Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)
- Specificity
- The Fab protein ranibizumab specifically binds to the human VEGF-A.
- Characteristics
- Recombinant Humanized Monoclonal Antibody Fragment (Fab) generated from the same parent mouse antibody as bevacizumab.
- Purification
- Protein A affinity column
- Purity
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- Sterility
- 0.2 μm filtered
- Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method.
- Immunogen
- The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.
-
-
- Application Notes
- Functional assay, neutralization.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
- Preservative
- Without preservative
- Handling Advice
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- Expiry Date
- 12 months
-
- Target
- VEGF (Ranibizumab Biosimilar)
- Abstract
- VEGF (Ranibizumab Biosimilar) Products
- Synonyms
- MVCD1 antibody, VEGF antibody, VPF antibody, vascular endothelial growth factor A antibody, VEGFA antibody
- Target Type
- Biosimilar
- Background
-
The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.
Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.
-
You are here:
